Related Experiment Videos
Prophylactic cryoprecipitate in congenital afibrinogenemia
R C Rodriguez1, G R Buchanan, M S Clanton
1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235-9063.
Clinical Pediatrics
|November 1, 1988
Summary
Prophylactic cryoprecipitate infusions effectively prevented serious hemorrhage in two siblings with congenital afibrinogenemia. This fibrinogen replacement therapy showed no adverse effects, offering a viable treatment for this rare bleeding disorder.
Area of Science:
- Hematology
- Pediatrics
- Rare Diseases
Background:
- Congenital afibrinogenemia is a rare inherited bleeding disorder characterized by a complete absence of fibrinogen.
- Managing this condition in early childhood often involves preventing serious hemorrhage.
- Previous treatment strategies may have limitations or associated risks.
Observation:
- Two siblings diagnosed with congenital afibrinogenemia were treated prophylactically.
- Cryoprecipitate, a blood product rich in fibrinogen, was administered regularly.
- Infusions were given every 7-10 days for extended periods (15 and 24 months).
Findings:
- Prophylactic cryoprecipitate infusions nearly completely prevented serious hemorrhage during the treatment period.
- No adverse side effects were observed in either sibling during cryoprecipitate administration.
- The long half-life of fibrinogen makes cryoprecipitate a practical prophylactic option.
Implications:
- Cryoprecipitate prophylaxis is a safe and effective strategy for managing congenital afibrinogenemia in children.
- This approach offers a promising method to prevent bleeding complications in affected individuals.
- Consideration of cryoprecipitate prophylaxis should be extended to other patients with this rare disorder.